Immuron's body of evidence that IMM-124E and Travelan are effective at controlling inflammation in the gut, such as in the liver and colon, via the LPS bacterial-endotoxin pathway is really starting to become overwhelming at this point (NASH Phase 2 results, Shigella primate results, colitis animal model results, Passport Health endorsement, Sanyal, Diehl, Rogler, U.S. NIH fully funded trials, Army/Navy involvement, etc.).
And we continue to trade at a $30 million USD market cap w/ only 3.53 million outstanding shares (based on U.S. conversion). When the market finally discovers this, I believe the share price will soar astronomically.
Immuron's body of evidence that IMM-124E and Travelan are...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $23.93M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.5¢ | $1.158K | 11.03K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9352 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 251204 | 4 |
View Market Depth
| Last trade - 10.48am 27/08/2024 (20 minute delay) ? |
| IMC (ASX) Chart |